HC Wainwright & Co. Reiterates Buy on Acurx Pharmaceuticals, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Acurx Pharmaceuticals (NASDAQ:ACXP) and maintained a price target of $12.

May 16, 2024 | 10:44 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Acurx Pharmaceuticals and maintained a price target of $12, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $12 price target by a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and could lead to a short-term increase in ACXP's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100